Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of skin infections. Recent case series describe severe community-acquired pneumonia (CAP) caused by MRSA, but the prevalence and risk factors are unknown.
Staphylococcus aureus is an established but uncommon cause of community-acquired pneumonia (CAP) [1] [2] [3] [4] [5] often associated with influenza. Methicillin-resistant S. aureus (MRSA) has emerged as a common cause of community-associated S. aureus infections and is now the most frequent etiology of skin and soft tissue infections treated in many US emergency departments (EDs) [6] . Many case series reports of MRSA CAP describe severe, necrotizing pneumonia with high mortality in previously healthy young individuals [7] [8] [9] [10] [11] [12] [13] .
Case series are limited by the lack of a denominator, preventing calculation of the proportion of CAP cases caused by MRSA, knowledge of which could influence empirical antimicrobial therapy. Current Infectious Diseases Society of America (IDSA) and America Thoracic Society (ATS) guidelines for CAP treatment state ''community-associated MRSA CAP remains rare in most communities but is expected to be an emerging problem in CAP treatment'' [14] . These guidelines do not recommend routine empiric antimicrobial therapy directed against MRSA. Vancomycin or linezolid is recommended ''if community-associated MRSA is a consideration,'' but the threshold prevalence or clinical features that should prompt inclusion of these agents is not specified.
The objectives of this study were to determine the proportion of CAP caused by MRSA among adult patients admitted to the hospital through the ED and to identify factors associated with MRSA.
METHODS
A prospective, observational prevalence study was conducted among patients presenting to 12 urban, university-affiliated EDs, the EMERGEncy ID NET study network [15] . Institutional review board approval was obtained at all sites.
Adults (aged $18 years) admitted to the hospital with an ED diagnosis of pneumonia during 2 subsequent influenza seasons (January-April 2006 at 9 sites and November 2006-April 2007 at 11 sites) were enrolled. Residents of long-term care facilities and patients hospitalized in the last month were excluded. Emergency physicians or study coordinators collected data at bedside, including demographics, symptoms, comorbidities, MRSA risk factors (eg, prior MRSA infection, household contact, recent hospitalization), chest radiograph findings, ED interventions (antibiotics, pressors, intubation), and disposition. Patients with hospital discharge diagnoses that did not include pneumonia were excluded. Study coordinators obtained laboratory and hospitalization follow-up data by medical record review approximately 2 weeks after enrollment.
Treating physicians determined diagnostic testing and management, including the collection of respiratory and blood cultures and antibiotic treatment. Initial culture and Gram stain results were recorded if performed in the ED or upon admission. Results of urine antigen tests or serologic tests for atypical pathogens were not collected. Additional information on treatment and outcome was collected on subjects from whom S. aureus was isolated.
Site hospital laboratories performed respiratory and blood culture and susceptibility testing using standard techniques [16] . Antimicrobial susceptibility of S. aureus isolates was determined at each laboratory for their in-house panel of routinely tested agents. Minimum inhibitory concentration breakpoints and quality control protocols were performed according to Clinical and Laboratory Standards Institute standards [17] .
Two investigators (D. A. T. and G. J. M.) reviewed culture results to assign the pneumonia etiology. Established pneumonia pathogens (eg, S. pneumoniae, S. aureus) were categorized as etiologic if cultured either from blood or pleural fluid or from other respiratory specimens in association with .25 white blood cells per high-power field and concordant Gram stain findings (ie, predominance of an organism with consistent morphology). Possible pneumonia pathogens (eg, alphahemolytic streptococci) were categorized as etiologic if cultured from: (1) multiple blood specimens; (2) 1 blood specimen in association with either clinical findings of bacteremia (eg, fever, tachycardia), or a concordant respiratory specimen culture result with #25 white blood cells per high-power field; or (3) a respiratory specimen with .25 white blood cells per high-power field. Organisms such as coagulase-negative staphylococci and diphtheroids were considered contaminants.
Data were analyzed using SAS version 9.1 (SAS Institute Inc). Descriptive statistics were used to summarize patient characteristics and MRSA prevalence. Relative risks and 95% confidence intervals were calculated using an online statistical calculator (http://statpages.org/ctab232.html) to describe associations between clinical and epidemiologic characteristics of patients with MRSA.
Staphylococcus aureus isolates were sent to the Centers for Disease Control and Prevention (CDC) for further analysis, including real-time multiplex polymerase chain reaction to detect genes encoding staphylococcal toxic shock syndrome toxin 1 (TSST-1; tst), Panton-Valentine leukocidin (PVL) (pvl; lukS-PV), S. aureus-specific thermonuclease (nuc), and mecA (personal communication GEF/BL). DNA extraction, SCCmec complex assignment [18] , and SmaI pulsed-field gel electrophoresis typing were performed as previously described [19] .
Audits were performed to determine if missed cases were different than enrolled cases. Emergency department logs were reviewed to identify patients admitted with pneumonia who were not enrolled. Those with a hospital discharge diagnosis of pneumonia were identified as missed cases, and limited data were extracted to compare missed and enrolled patients.
RESULTS
A total of 884 subjects were enrolled: 230 between January and April 2006 and 654 between November 2006 and April 2007. We excluded 187 subjects whose discharge diagnoses did not include pneumonia (eg, chronic obstructive pulmonary disease, bronchitis, congestive heart failure [CHF]). We also excluded 87 subjects who were hospitalized in the previous month (17 had both exclusions). The final analysis group consisted of 627 subjects with an ED and hospital discharge diagnosis of pneumonia (Table 1) .
Among 595 (95%) patients with blood and/or respiratory cultures performed, a pathogen was identified in 102 (17%). Fifty-five were identified from blood cultures only, 41 from respiratory cultures only, and 6 from both. MRSA was identified as a pathogen in 14 (2.4%; 95% confidence interval, 1.1%-3.6%). Methicillin-resistant S. aureus prevalence by site ranged from 0% to 5% (Table 2 ). Other identified pathogens included S. pneumoniae (57; 9.6%); methicillinsusceptible S. aureus (MSSA) (9; 1.5%); Klebsiella pneumoniae (4; 0.7%); Haemophilus influenzae (2; 0.3%); and others (14; 2.4%). Of 579 (92%) patients who had blood cultures, 61 (11%) yielded a pathogen, 38 (7%) yielded contaminants, and 480 (83%) had no growth. Of 313 (50%) patients with respiratory cultures, 47 (15%) yielded a pathogen, 34 (11%) yielded contaminants, and 232 (74%) had no growth. Of 268 respiratory specimens with source information, 219 (82%) were expectorated sputum, 28 (10%) were induced sputum, 11 (4%) were endotracheal tube aspirate, 7 (3%) were bronchoalveolar lavage, 2 (0.7%) were transtracheal aspirate, and 1 (0.4%) was pleural fluid.
Of 23 patients with S. aureus pneumonia, blood cultures from 9 (39%) of 23 and respiratory cultures from 17 (89%; 15 expectorated sputum, 1 endotracheal aspirate, 1 pleural fluid) of 19 grew S. aureus. Of 14 patients with MRSA pneumonia, blood cultures from 6 (43%) of 14 and respiratory cultures from 10 (91%; 7 expectorated sputum, 1 induced sputum, 1 endotracheal aspirate, 1 pleural fluid) of 11 grew MRSA. In comparison, of 57 patients with pneumococcal pneumonia, blood cultures from 43 (75%) of 57 and respiratory cultures from 16 (47%) of 34 grew S. pneumoniae.
Influenza rapid testing was performed on 67 (11%) subjects; 1 was positive for influenza A. Influenza cultures were performed on 35 (6%); all were negative. No influenza testing was performed on subjects with MRSA.
Of 23 S. aureus blood or respiratory isolates, 14 (4 blood and 10 respiratory) were further characterized at the CDC. These included 5 pvl-negative MSSA (pulsed-field types USA700, USA900, USA800, Group D, Group B) and 9 MRSA isolates (all pulsed-field type USA300, SCCmec type IV, pvl positive, and TSST negative).
Antimicrobial resistance observed among the 14 MRSA isolates included resistance to clindamycin (18%; 2 of 11), ciprofloxacin (50%; 2 of 4), erythromycin (87%; 7 of 8), and levofloxacin (29%; 2 of 7; 3 were intermediate), but not to moxifloxacin (0 of 1), tetracycline (0 of 12), or trimethoprimsulfamethoxazole (0 of 14).
Patients with MRSA pneumonia were of similar age and sex distribution; however, they appeared to be more ill and have more extensive chest radiographic abnormalities than non-MRSA patients (Table 1) . Epidemiological features significantly associated with MRSA etiology included history of cirrhosis, history of MRSA, admission to a long-term care facility in the previous year, and close contact with someone with a skin infection in the previous month. Clinical features associated with MRSA included multiple infiltrates or cavitary disease on chest radiograph, and comatose state, intubation, receipt of pressors, or death in the ED. Of 195 patients with at least 1 of these features, 10 (5%) had MRSA; among 425 patients with none of the features, 4 (1%) had MRSA. Among 14 patients with MRSA pneumonia, 3 were initially admitted to the intensive care unit (ICU) and 2 were later transferred to the ICU. One patient died in the ED, and 1 died in the ICU (14% mortality).
Among all 627 pneumonia patients, antibiotics were administered to 607 in the ED; 404 (67%) received a cephalosporin, 359 (59%) macrolide, 154 (25%) fluoroquinolone, 59 (10%) vancomycin, 31 (5%) trimethoprim-sulfamethoxazole, 16 (3%) clindamycin, 22 (4%) tetracycline, 1 (0.2%) rifampin, 4 (1%) carbapenem, and 16 (3%) other antibiotics. Among the 14 MRSA cases, 4 (29%) received an initial empiric regimen (17) 56 (88) 9 ( with presumed in vitro activity against community MRSA strains (vancomycin or clindamycin; none received linezolid). Case-finding audits revealed that approximately 43% of eligible patients were enrolled. We identified 841 nonenrolled patients with hospital admission diagnosis of pneumonia from ED logs during enrollment periods. We were unable to determine how many would have been excluded for reasons such as prior hospitalization or long-term care facility residence, so our actual enrolled proportion may have been greater. Compared with enrolled patients, nonenrolled patients were similar in age (median age, 57 years; range, 18-97 years), sex (54% male), and race (36% white or Hispanic, 41% black, 5% other [18% unknown]). Methicillin-resistant S. aureus was isolated from 7 of 699 (1%) nonenrolled patients from whom blood cultures were obtained (vs 1% among enrolled) and 20 of 426 (5%) from whom respiratory cultures were obtained (vs 3% among enrolled).
DISCUSSION
Although MRSA has emerged as the most common cause of skin and soft tissue infections in much of the United States and severe MRSA CAP cases have been reported, we are unaware of any previous investigation examining MRSA prevalence among unselected patients with CAP. Our results suggest that MRSA remains an uncommon cause of CAP. In this network of US emergency departments, the prevalence of MRSA as the identified etiology of CAP was approximately 2%, ranging from 0% to 5% by site, and 5% for patients admitted to the ICU. Patients with MRSA appeared to be more ill upon presentation with more extensive chest radiographic abnormalities.
Our results are similar to several prior CAP studies done prior to emergence of MRSA in the community, in which no pathogen was identified in the majority of patients, S. pneumoniae was most common among those with an identified pathogen, and S. aureus prevalence was very low, even among patients admitted to the ICU [1, 2, 4, 14] . Because our study did not require specialized testing, our results may be more reflective of usual clinical practice in which ''atypical'' organisms are probably underdiagnosed.
In recent S. aureus CAP case series, median patient ages were 17-21 years, mortality ranged 29%-60%, and most patients had concurrent influenza [7] [8] [9] [10] [11] [12] . In our study population, we did not find as high a mortality rate or an association of MRSA with younger age. We suspect that severe illness in younger patients is likely overrepresented in published case series. Although an association between influenza and S. aureus pneumonia has been well established in the literature [11, 20, 21] , the infrequency of influenza testing performed on our study subjects prevented us from assessing an association between MRSA and confirmed influenza.
In-hospital mortality was 14% among MRSA patients in our series; we did not collect mortality data for non-MRSA cases. Our mortality rate for MRSA pneumonia is higher than the 8.8% overall mortality found in a prior study of unselected CAP patients admitted to the hospital [4] and is similar to the 13% mortality found in a recent case series of MRSA pneumonia [22] . Although based on a small number of cases, our findings that MRSA pneumonia patients were more likely to require intubation or pressors or to die in the ED suggest that these patients may be more severely ill.
All characterized MRSA isolates were USA300, the predominant pulsed-field type circulating in the community in the United States, and all contained genes encoding PVL. Although the role of PVL in the pathogenesis of S. aureus infections is unclear, PVL-positive strains have been associated with spontaneous skin/soft-tissue infections and necrotizing pneumonia [23] . Our findings of more severe clinical illness and relatively high mortality associated with PVL-positive MRSA CAP are consistent with these prior observations.
Although we identified several clinical and epidemiologic factors associated with MRSA infection, the presence or absence of these factors does not appear useful to guide decisions about empirical antibiotics. Only a small proportion of patients with $1 of these clinical features had MRSA, and 4 (29%) of 14 patients with MRSA had none of these features. Therefore, it does not appear that an MRSA-active empiric antimicrobial regimen can be recommended based on identification of a subgroup of CAP patients at risk for MRSA infection. We did not identify factors a priori to test in a multivariable regression model; however, future studies could assess whether the MRSA-associated variables we identified could be used to predict MRSA as the etiologic agent of CAP in a multivariable model.
Most patients in our series did not receive initial empiric treatment that covered MRSA; this is consistent with current IDSA/ATS CAP treatment guidelines, which do not recommend routine empiric MRSA coverage for CAP [14] . However, despite the low prevalence of MRSA, even among CAP patients admitted to the ICU, our findings support the inclusion of agents such as vancomycin or linezolid to provide MRSA coverage for patients with severe, life-threatening CAP, as is consistent with recently published IDSA guidelines for treatment of MRSA infections [24] . Methicillin-resistant S. aureus was relatively more common and empiric broad spectrum therapy justifiable in these sicker patients. One of the IDSA/ATSrecommended regimens for treatment of inpatients with CAP, a third-generation cephalosporin plus doxycycline, could be an option to provide MRSA coverage in less severely ill patients, because all MRSA strains in our study were susceptible to tetracycline. However we are not aware of any data on the efficacy of doxycycline for treatment of MRSA pneumonia.
Our study has several limitations. We were not successful in enrolling consecutive patients, although case audits indicate that nonenrolled patients had similar demographic characteristics and MRSA prevalence. Although our network includes diverse geographic areas in the United States, patients at urban academic medical centers may not reflect populations seen in other settings. We excluded patients in long-term care or hospitalized in the last month, but some patients had other healthcare exposures and may have had healthcare-associated infections. The sensitivity and specificity of respiratory cultures for identifying MRSA pneumonia are not well established, so it is possible that some cases were misclassified. Finally, some clinical features we found to be associated with MRSA may be associated with S. aureus in general, as our analysis focused on factors associated with MRSA versus non-MRSA CAP.
As with most studies of CAP, a diagnostic gold standard, such as transthoracic needle aspiration, was not employed, and a pathogen was identified from a minority of patients. Because the extent to which patients had diagnostic testing was left up to the treating physicians, diagnostic efforts were not as extensive as would occur in some clinical trials and focused etiologic research studies. However, since the network consisted of major university-affiliated medical centers, we believe the diagnostic investigation was relatively robust, and the prevalence of MRSA is likely higher than would be found in typical community practice. Staphylococcus aureus (including MRSA) was less often identified by blood cultures and more often by respiratory cultures than pneumococcal cases. Because almost all patients had blood cultures taken but only about 50% had respiratory specimens collected, it is possible that the prevalence of S. aureus would have been greater if more respiratory specimens were cultured. However, assuming the observed yield of MRSA, had all patients had respiratory specimens obtained, the prevalence of MRSA would still have been ,5%.
Despite widespread emergence of MRSA as a cause of community-associated skin infections and case series describing community strains of MRSA as a cause of severe CAP, MRSA appears to remain an uncommon cause of CAP in these study sites. Ongoing surveillance is, however, warranted. Empiric therapy with coverage for MRSA appears justified in patients with severe CAP until MRSA has been excluded through aggressive diagnostic testing for an etiology. 
